RayKnowChina Research Map
Shortlist

WuxiNanjing Medical University

Affiliated Wuxi People's Hospital of Nanjing Medical University

无锡市人民医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Wuxi People's Hospital of Nanjing Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Stomach cancer胃癌16 papers led
  2. Osteosarcoma骨肉瘤2 papers led
  3. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  4. Multiple myeloma多发性骨髓瘤4 papers led
  5. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  6. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  7. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  8. IgA nephropathyIgA 肾病0 papers led
  9. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  10. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Stomach cancer

胃癌

Led 16 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 4420232024: 4420242025: 552025

3 hospitals in Wuxi for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07600125

    Age 18 years to Not stated (registered criteria)

    Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImmunotherapy & targeted drugsImaging & AI
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led16
  1. An integrative multi-omics study to identify candidate DNA methylation biomarkers associated with gastric cancer prognosis.2025Archives of toxicology
  2. Tumor-derived PRMT1 suppresses macrophage antitumor activity by inhibiting cGAS/STING signaling in gastric cancer cells.2025Cell death & diseaseFree full text
  3. Single-cell eQTL mapping reveals cell-type-specific genes associated with the risk of gastric cancer.2025Cell genomicsFree full text
  4. Plasma Metabolomic Signatures of H. pylori Infection, Alcohol Drinking, Smoking, and Risk of Gastric Cancer.2025Molecular carcinogenesis
  5. Helicobacter pylori Promoted miR-196a/b-5p Expression and Accelerated Tumorigenesis of the Gastric Mucosa by Targeting IGF2BP1 and Activating PI3K-Akt Signaling Pathway.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  6. The diagnostic value of serum trefoil factor 3 and pepsinogen combination in chronic atrophic gastritis: a retrospective study based on a gastric cancer screening cohort in the community population.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  7. Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.2024Cancer biomarkers : section A of Disease markersFree full text
  8. Long non-coding RNA NRAV in the 12q24.31 risk locus drives gastric cancer development through glucose metabolism reprogramming.2024Carcinogenesis
  9. Multiple neuroendocrine tumors in the stomach, duodenum and pancreas of a MEN1 patient.2024Revista espanola de enfermedades digestivas
  10. Clinicopathological analysis of a type of "low grade" poorly cohesive gastric adenocarcinoma not otherwise specified with a good prognosis.2023Annals of diagnostic pathology
  11. GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.2023BMC cancerFree full text
  12. Identification of high-risk factors associated with mortality at 1-, 3-, and 5-year intervals in gastric cancer patients undergoing radical surgery and immunotherapy: an 8-year multicenter retrospective analysis.2023Frontiers in cellular and infection microbiologyFree full text
  13. Prediction model of liver metastasis risk in patients with gastric cancer: A population-based study.2023MedicineFree full text
  14. Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.2022Pathology oncology research : PORFree full text
  15. Effect of NTSR1 on the Proliferation and Invasion of Gastric Adenocarcinoma Cells, the Underlying Mechanism, and Clinical Role.2021Annals of clinical and laboratory science
  16. Clinicopathological significance of primitive phenotypes in early gastric cancer with differentiated histology.2021Diagnostic pathologyFree full text
Chinese-language papers (not in the count)1
  1. [Grading of tumor budding in intestinal-type early gastric adenocarcinoma and its role in assessing the risk of lymph node metastasis].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status2
  1. Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract CancersRecruitingNCT07600125Study siteStart 2026-08
  2. Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home ScenariosCompletedNCT06848400Study siteN/AStart 2025-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Wuxi for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wuxi for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. [Malignant gastrointestinal stromal tumors in pleural effusion: report of a case].2020Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Wuxi for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersNeurology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

2 hospitals in Wuxi for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led5
  1. PCR array analysis reveals a novel expression profile of ferroptosis-related genes in idiopathic pulmonary fibrosis.2025BMC pulmonary medicine
  2. Cytokine Expression Profiling in Idiopathic Pulmonary Fibrosis: Insights From Integrative Proteomic Analysis.2025Canadian respiratory journal
  3. Idiopathic Pulmonary Fibrosis Is Associated With Type 1 Diabetes: A Two-Sample Mendelian Randomization Study.2025The journal of gene medicine
  4. Exploring the causal relationship between immune cells and idiopathic pulmonary fibrosis: a bi-directional Mendelian randomization study.2024BMC pulmonary medicine
  5. Deficiency of HtrA3 Attenuates Bleomycin-Induced Pulmonary Fibrosis Via TGF-β1/Smad Signaling Pathway.2023Lung
Chinese-language papers (not in the count)4
  1. [Outcomes of idiopathic pulmonary fibrosis patients with high body mass index undergoing extracorporeal membrane oxygenation support].2024Zhonghua wei zhong bing ji jiu yi xue
  2. [Expression and protective effect of chemerin in idiopathic pulmonary fibrosis].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [Risk factors of early death after lung transplantation in patients with idiopathic pulmonary fibrosis complicated with pulmonary arterial hypertension].2023Zhonghua wei zhong bing ji jiu yi xue
  4. [Risk factors analysis for 1-year postoperative survival of patients with benign end-stage lung diseases after lung transplantation].2021Zhonghua wei zhong bing ji jiu yi xue
Earlier papers (2016–2020)3
  1. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis.2019The clinical respiratory journal
  2. [Value of preoperative pulmonary artery diastolic pressure on predicting primary graft dysfunction after bilateral lung transplantation for patients with idiopathic pulmonary fibrosis].2017Zhonghua wei zhong bing ji jiu yi xue
  3. [Outcomes after singleversus bilateral lung transplantation for idiopathic pulmonary fibrosis].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status5
  1. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Wuxi for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Clinicopathological and molecular genetic characteristics of multifocal micronodular pneumocyte hyperplasia (MMPH)].2025Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wuxi for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. [A case of dilated cardiomyopathy caused by Becker muscular dystrophy].2019Zhonghua xin xue guan bing za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Wuxi for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status4
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Wuxi for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Wuxi for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

无锡市人民医院

Affiliated Wuxi People's Hospital of Nanjing Medical University

无锡

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data